Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
From Principle to Practice: New Checklist Supports Patient Engagement in Rare Disease Value Research
The Center for Innovation & Value Research launched the Rare Disease Patient Engagement (RDPE) Guidance and Checklist, a practical toolkit to embed patient and caregiver input throughout rare‑disease comparative effectiveness research, value assessment, and economic modeling. The resource bundles best‑practice guidance, a structured PDF checklist for real‑time documentation, and a visual executive summary to standardize engagement activities. Developed with the EveryLife Foundation and NORD and funded by a PCORI Engagement Award plus support from Alexion and AstraZeneca, the checklist targets researchers, advocacy groups, payers, and policy makers. Users are urged to share implementation examples, enabling continuous refinement of patient‑centered methods in 2026 and beyond.
Curbside Consult with Dr. Jayne 3/2/26
The article sketches a typical week for a clinical informaticist, showing how patient care, system design, feedback loops, governance, safety, and evidence assessment intertwine. It highlights that a single day can involve everything from bedside interaction to long‑term technology strategy....
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
The large‑cap pharmaceutical sector is rebounding in 2026 after a muted 2025, buoyed by strong quarterly results, aggressive M&A, and robust pipeline activity. Zacks ranks the industry at #172, but it posted a 10.8% gain over the past year, outpacing...
Vueway Expands Pediatric Use: Alberto Spinazzi Shares Bracco Group’s Vision
The European Union has granted approval for Vueway (gadopiclenol) to be used in neonates, infants, and toddlers, marking a pivotal expansion of pediatric MRI contrast agents. Vueway delivers diagnostic‑grade imaging at half the dose of conventional macrocyclic GBCAs, thanks to...
Safety Concerns Spur Aardvark to Halt Key Prader-Willi Drug Trial
Biotech Aardvark Therapeutics announced a voluntary pause of the Phase 3 HERO trial for its Prader‑Willi drug ARD‑101 after routine safety monitoring identified reversible cardiac observations in healthy volunteers receiving supratherapeutic doses. The pause affects both the main trial and an...
Advocacy Bias Keeps Unproven DMD Therapy, Blocks HD Progress
The Duchenne muscular dystrophy patient & advocacy community keeps a gene therapy and multiple drugs on the US market, stopping the FDA from taking action, despite failed confirmatory clinical trials showing no efficacy and questionable safety. The Huntington's disease patient and...
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
Merck and Pfizer’s Keytruda‑Padcev doublet delivered a dramatic survival advantage in the Phase 3 EV‑304 study of muscle‑invasive bladder cancer. The regimen cut the risk of disease progression, recurrence or death by 47% compared with gemcitabine‑cisplatin and lowered overall‑mortality risk by...
Sexual Health Education: HHS Could Improve Efforts to Assess Grantee Performance
The GAO report finds that the Department of Health and Human Services (HHS) administers Sexual Risk Avoidance Education (SRAE) grants but relies mainly on near‑term performance measures focused on program reach rather than youth outcomes. While HHS reviews curricula for...
Tuesday Health Expands Footprint to Ohio With Buckeye Health Plan Partnership
Tuesday Health has partnered with Buckeye Health Plan to extend its palliative‑care model across Ohio, reaching the plan’s 400,000 Medicaid, Medicare and Marketplace members. The collaboration delivers an interdisciplinary team—including nurses, social workers, NPs and physicians—through in‑person, hybrid and virtual...
Best Practices for Applying HDX-MS to FBLD
A recent open‑access study demonstrates that hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) can reliably map binding sites of extremely weak fragment hits (up to 7 mM KD) against Cyclophilin D. By optimizing protein concentration at 10 µM and testing fragments at 2.5‑10 mM, the...
Alcidion Delivering ‘Software as a Medical Device’ AI Capabilities in Both Australia and the UK
Alcidion announced that its Miya Precision Concept Detection AI feature has achieved Class 1 medical device registration on Australia’s ARTG (ID 522634) and the UK’s MHRA. The tool parses clinicians’ free‑text notes, proposes SNOMED CT codes and streamlines documentation while requiring clinician validation....
Big Pharma’s Next Entrant Could Come From China
Chinese drugmakers, led by Jiangsu Hengrui Pharmaceuticals, are emerging as global biotech contenders. Hengrui topped 2024 trial sponsorship, boasts a pipeline of 100 investigational drugs and 400 trials, and secured a $500 million partnership with GSK that could yield $12 billion. Analysts...
Radiology Artificial Intelligence Firm Asks FDA to Exempt Certain Devices From Premarket Review
Harrison.ai filed a citizen petition asking the FDA to grant optional pre‑market exemption for radiology computer‑aided detection (CAD) devices, allowing manufacturers with an existing cleared product to launch similar tools without a new 510(k). The agency must issue a rapid...
You Don’t Notice Public Health Until It’s Gone: The True Costs of Cutting the Workforce - Voices #29
Emma Aston, a former CDC health communicator, details how a 2025 Reduction in Force eliminated roughly a quarter of the agency’s workforce, silencing key public‑health messaging. The cuts halted campaigns on tobacco, HIV, and flu, while new executive orders imposed...
FDA Demands Sham‑controlled Trial for uniQure’s AMT‑130
$QURE AMT-130 update: Still blocked The FDA stated that it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for...
Flare's GU26 Targets Undruggable PPAR‑γ, Yet Caveats Remain
Who's heard of Flare Therapeutics? #GU26 late-breaker shows promise in hitting "undruggable" PPAR-γ target, with a few major caveats. Via @ApexOnco -> https://t.co/1GepvywtL0
Gene Therapy’s Inflexion Point: From Scientific Breakthrough to Systemic Transformation
Gene therapy for sickle cell disease has moved from experimental promise to an actionable clinical reality, with early CRISPR‑based treatments already cutting crises and hospital stays. A recent Sanius Health survey of 94 patients shows strong interest—71% want more information—yet...
Europe Braces for Fallout of Trump's Drug Pricing Plan
“Nobody wants to feel cornered:" Europe braces for the fallout of Trump's drug pricing plan https://t.co/HZjZH0mdCU
FDA Limits NTLA Gene Therapy to Mild Cases, Undermining Demand
$NTLA drug is off hold but now being restricted by the FDA to the least severe/sick patients, which would logically be those least likely to want/need an experimental gene editing therapy. Existing options will dominate. Target/disease selection is a...
Philosophy in Medicine: Why Doctors Need to Ask “Why”
An EMT recounts a harrowing transport of a stroke‑survivor, Molly, highlighting how standard stair‑chair equipment failed to accommodate her size and mobility limitations, leading to injury and indignity. The author uses the incident to illustrate structural violence and the marginalization...
MRK's Ovarian Cancer Claim Rejected by FDA, EMA
$MRK claims a survival benefit in ovarian cancer irrespective of PD-L1 status, but FDA & EMA say BS. Via @ApexOnco -> https://t.co/Cld1O7Uuvp #ESGO26
Nuclear Medicine Firm Shine Technologies Raises $240M
Shine Technologies announced a $240 million financing round led by Patrick Soon‑Shiong’s NantWorks, bringing its total capital raised to over $1 billion. The infusion will accelerate the company’s commercial fusion initiatives and expand its Lu‑177 isotope production, a cornerstone of targeted cancer...
DHSC Launches Industry Readiness Survey on Value Based Procurement
The UK Department of Health and Social Care (DHSC) has launched an industry‑readiness survey on Value Based Procurement (VBP), targeting MedTech and health‑technology firms. The ten‑minute questionnaire seeks a single consolidated response per company and must be submitted by 27 March....
HDRS Appointment Is Moment to Create Momentum
The UK Health Data Research Service (HDRS) is set to launch later this year as a secure, single gateway for national health and care datasets, aiming to unlock the country’s extensive longitudinal records. The government announced Melanie Ivarsson, a former...
Changes in the Gut Microbiome Drive Age-Related Intestinal Barrier Dysfunction
Researchers identified that the aging gut microbiome harbors increased Klebsiella aerogenes, which elevates histamine production and compromises intestinal barrier integrity. The excess histamine suppresses Nlrp6 expression, disrupting LC3‑mediated autophagy and intensifying inflammation in septic models. Experiments showed that lowering histamine...
Segmed Partners with Verily to Expand Access to Real-World Imaging Data
Segmed, a leader in real‑world medical imaging, announced a partnership with Verily to make its de‑identified, diagnostic‑grade imaging datasets available on Verily’s AI‑native Pre Exchange and Workbench platforms. The initial offering is a longitudinal breast‑cancer cohort featuring digital breast tomosynthesis...
Real-World Data Brings New Insights to Natural History of Disease Studies
Real‑world data (RWD) is reshaping natural history studies by delivering longitudinal, patient‑level information that was previously only obtainable through costly prospective trials. Advances in artificial intelligence and natural language processing now allow rapid extraction of structured data from unstructured sources...
Clinical Labs Gain Ground with Noninvasive Dd-cfDNA Transplant Surveillance
A new donor‑derived cell‑free DNA (dd‑cfDNA) blood test is transforming post‑transplant surveillance by providing real‑time, noninvasive insight into graft health. The assay quantifies donor DNA fragments released when a transplanted organ is injured, offering a high negative predictive value that...
Ascendis’ Yuviwel (Navepegritide) Receives the US FDA Accelerated Approval for Achondroplasia
The U.S. FDA granted accelerated approval to Ascendis’ Yuviwel (navepegritide) for increasing linear growth in children aged two years and older with achondroplasia and open epiphyses. Approval rests on three placebo‑controlled trials and up to three years of open‑label extension...
Why Claims Data Underestimates Mental Health Risk
Employers often rely on isolated claims or EAP call counts, which dramatically understate the true scale of behavioral health issues in the workforce. By aggregating medical, pharmacy, and EAP data—and even website analytics—companies can capture both prevalence and cost, revealing...
NHS Evaluation Shows up to 75% Reduction in Hospital Visits in Care Homes Using Nobi Smart Lights
An independent NHS evaluation across seven Suffolk care homes using Nobi Smart Lights reported up to a 75% reduction in falls‑related hospital admissions and up to a 65% drop in ambulance call‑outs. The study compared six months of baseline data...
Why It’s Critical to Close Open Steps in Cell Therapy Manufacturing
Cell therapy manufacturing is vulnerable to contamination because living cells cannot be terminally sterilized. Regulatory bodies such as EU GMP Annex 1 and the FDA now require risk‑based contamination control strategies that prioritize closed, sterile, and automated processes. Closing open steps...
Sanofi Receives CHMP Recommendation for Dupixent Expansion in Europe
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending Dupixent (dupilumab) for paediatric chronic spontaneous urticaria (CSU) in children aged 2‑11. The recommendation is based on robust Phase III data from the LIBERTY‑CUPID...
FDA Grants PMA to Synergy’s Cervical Disc
Synergy Spine Solutions received FDA pre‑market approval for its Synergy Disc, a cervical artificial disc designed to preserve motion and correct spinal alignment. Clinical data showed an 87.1% composite success rate at 24 months, with significantly lower neck‑pain and arm‑pain...
Opus Genetics Reports Phase I/II Trial Results of OPGx-BEST1 Gene Therapy
Opus Genetics presented early Phase I/II data for its OPGx‑BEST1 gene therapy targeting best vitelliform macular dystrophy and autosomal‑recessive bestrophinopathy. In a sentinel 63‑year‑old participant, the treatment was well tolerated and delivered a 12‑letter gain in best‑corrected visual acuity after...
BioMarin Receives FDA Approval for Palynziq Use in Adolescents
BioMarin’s enzyme substitution therapy Palynziq received FDA approval for use in adolescents aged 12 and older with phenylketonuria (PKU). The decision was based on Phase III PEGASUS trial results showing 44.4% of participants lowered blood phenylalanine below guideline levels, with a...
LM PAEK Can Outperforms PEEK In Certain Applications
A Drexel‑led study demonstrated that low‑melt polyaryletherketone (LM PAEK) can be fused‑filament‑fabricated into porous knee‑revision cones that outperform traditional PEEK in shear strength and stiffness. Using a Taguchi L8 design, the researchers printed 64 cylindrical surrogates with gyroid and diamond TPMS...
Harnessing Technology to Redefine Standards in GI Care
Gifthealth’s co‑founder John Romano outlines how AI‑driven pricing tools and automated patient‑support platforms can lower out‑of‑pocket costs and improve medication adherence for the 60 million Americans living with gastrointestinal diseases. By integrating real‑time claims adjudication, discount automation and personalized education, the...
18 UK Biotech Companies You Should Know About
The article profiles 18 UK biotech firms spanning oncology, immunology, regenerative medicine and AI‑driven drug design, highlighting recent milestones such as Amphista’s $30 million upfront deal with BMS, Autolus’ FDA and EU approvals for obe‑cel, and Isomorphic Labs’ $600 million raise to...
Kardi AI Is Scaling, MDR Class IIa Certified and Series A Ready
Kardi Ai, a Czech med‑tech firm, has secured EU MDR Class IIa certification and is expanding its long‑term ECG monitoring platform into the DACH region. The solution records heart rhythm for up to 12 months, uses AI to deliver physician‑ready reports within...
Interview: The Enduring Appeal of Alternative Medicine
Lewis A. Grossman's book "Choose Your Medicine" traced historic battles over alternative‑medicine freedom, a pattern echoed today as Health Secretary Robert F. Kennedy Jr. pushes to loosen FDA oversight of unapproved stem‑cell and peptide treatments. The interview highlights recurring public resistance...
Driving Innovation in Medical Motion Control
Motion control underpins modern medical devices such as surgical robots, imaging systems, and laboratory instruments, yet it remains a complex engineering hurdle. Dave Beckstoffer of Portescap highlights how early, collaborative partnerships with motion‑control specialists can streamline development and boost reliability....
Monolithic 3D Nanoelectrode Arrays on CMOS Circuitry for Scalable, High‐Resolution Neural Recording
Researchers have developed a monolithic 3D nanoelectrode array (HD‑NEA) that integrates 26,400 vertical nanowire electrodes directly onto commercial CMOS chips. The low‑temperature wafer‑scale post‑fabrication process maintains circuit functionality while delivering uniform, high‑yield electrode performance across 4‑inch wafers. In vitro recordings...
PHTI Breaks Down Barriers to Clinical AI
The Patient‑Centered Health Technology Initiative (PHTI) released a Clinical AI report built from a workshop with senior leaders across health systems, insurers, tech firms, and federal agencies. Participants identified policy, reimbursement, and evidence gaps as primary barriers to scaling AI...
X4 Pharmaceuticals’ Xolremdi (Mavorixafor) Receives the CHMP Positive Opinion for WHIM Syndrome
X4 Pharmaceuticals’ Xolremdi (mavorixafor) received a positive opinion from the European CHMP, recommending approval under exceptional circumstances with an EC decision expected in Q2 2026. The recommendation is based on the global Phase III 4WHIM trial involving 31 patients aged 12 and...
Ipsen Reports the CHMP Positive Opinion for Ojemda (Tovorafenib) for R/R BRAF-Altered Pediatric Low-Grade Glioma (pLGG)
European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending conditional approval of Ipsen’s Ojemda (tovorafenib) as monotherapy for pediatric low‑grade glioma with BRAF fusions, rearrangements or V600 mutations. The recommendation is based on...
Carriers See Higher Claims Severity Amid Medical, Social Inflation and Growth in AI‑Generated Fraud
North American insurers are confronting a surge in claim severity as medical inflation, social inflation, and AI‑generated fraud drive costs upward. The Gallagher Bassett 2026 Carrier Report shows 64% of carriers see more complex claims, with 56% pinpointing rising medical expenses...
The Mental Health Crisis Is Changing — Here’s What Insurers Need to Know
Life‑science firms face heightened D&O liability as stock volatility spikes around clinical trial readouts and regulatory decisions. Shareholder lawsuits often begin with books‑and‑records demands that probe whether public statements matched internal knowledge. The article stresses disciplined, consistent disclosure and early...
AI in Healthcare Revenue Cycle Management: Moving From Automation to Prediction
Healthcare revenue cycle leaders are shifting from rule‑based automation to AI‑driven predictive analytics. Machine‑learning models now scan claim data, documentation and payer behavior to flag denial risks before submission. Early corrections improve first‑pass acceptance, shorten cash cycles and reduce revenue...
Otsuka Medical Devices/Otsuka Pharmaceutical: Paradise Ultrasound Renal Denervation System for the Treatment of Resistant Hypertension, Now Covered by Insurance and...
Otsuka Medical Devices and Otsuka Pharmaceutical announced that Japan’s National Health Insurance will cover the Paradise™ Ultrasound Renal Denervation (uRDN) system starting March 1, with commercial sales beginning March 2. The device, developed by Recor Medical, targets resistant‑hypertension patients who remain uncontrolled...